~ Pune-based startup targets high-value Western patients with partnerships across India, Turkey, Mexico, and Thailand ~
Apr 06: CureMeAbroad, a Pune-based medical tourism startup, has achieved a $2.5 million annual revenue run rate within its first two quarters of operations, emerging as a fast-scaling player in the global healthcare mobility space.
The company has adopted a differentiated strategy by focusing on Western patients from markets such as the US, UK, Germany, and Australia, moving away from traditional medical tourism corridors linking India with Bangladesh, the Gulf Cooperation Council (GCC) region, and Africa—routes typically characterised by high volumes and lower margins.
Instead, CureMeAbroad operates in the high-value segment, facilitating procedures such as cosmetic surgery, in vitro fertilisation (IVF), fertility treatments, and surrogacy. According to the company, patient spending on its platform ranges from $5,000 to $80,000 per case, significantly higher than the sub-$5,000 average in conventional markets.
The startup has built a robust network spanning 11 countries, with partnerships across 350+ hospitals in key destinations including Mexico, Thailand, Turkey, South Korea, and India. This multi-geography model enables the platform to match patients with providers based on treatment needs, pricing, and location preferences, while also mitigating risks related to regional disruptions and pricing fluctuations.
“We identified that while access to global healthcare options has increased, patients, particularly in Western markets, continue to face challenges around trust and decision-making due to fragmented information,” said Aditya Oza, CEO & Founder, CureMeAbroad. “Our focus has been on simplifying this journey through verified information, real patient experiences, and end-to-end coordination.”
The company’s operations are powered by an AI-driven model, enabling a single care coordinator to manage 15–20 patients simultaneously across the entire treatment lifecycle, from initial inquiry to post-procedure care.
Currently, the platform handles 60–80 patient cases daily, with a growing share of business driven by customer advocacy. Approximately 38 per cent of revenue is generated through repeat patients and referrals, indicating increasing trust and satisfaction within its target segment.
Co-founder Mikhail Bohra highlighted the importance of quality partnerships in driving growth. “Building credibility with Western patients requires consistent quality standards. We have prioritised collaborations with hospitals and clinics that meet international benchmarks, which in turn strengthens patient confidence and fuels word-of-mouth growth,” he said.
Looking ahead, CureMeAbroad is developing a global discovery platform that will aggregate data on over 2,500 hospitals and 14,000 doctors, offering curated treatment plans, verified reviews, and comprehensive insights into the patient journey.
CureMeAbroad is yet to raise a seed round and is currently in conversations with investors.
The global medical tourism market is projected to reach $130 billion by 2030, with the Western patient segment remaining relatively underpenetrated. CureMeAbroad’s early traction signals a broader shift in how Indian startups approach international healthcare demand—transitioning from volume-driven models to a more premium, trust-led engagement strategy.
